JP Morgan Chase’s Cytokinetics CYTK Stock Holding History

JP Morgan Chase’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,900	Closed	-$248K	–	7599
2025 Q4	$248K	Buy	3,900 +2,000	+105%	+$124K	﹤0.01%	5427
2025 Q3	$104K	Buy	+1,900	New	+$78.3K	﹤0.01%	5878
2025 Q1	–	Sell	-6,000	Closed	-$282K	–	7378
2024 Q4	$282K	Sell	6,000 -30,000	-83%	-$1.56M	﹤0.01%	5327
2024 Q3	$1.9M	Buy	36,000 +35,000	+3,500%	+$1.95M	﹤0.01%	4044
2024 Q2	$54.2K	Sell	1,000 -35,000	-97%	-$2.11M	﹤0.01%	5822
2024 Q1	$2.52M	Buy	36,000 +23,500	+188%	+$1.82M	﹤0.01%	3661
2023 Q4	$1.04M	Buy	+12,500	New	+$453K	﹤0.01%	4305

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase's CYTK Position: Q1 2026 in Review

JP Morgan Chase reduced its Cytokinetics (CYTK) stake by 36% in Q1 2026, selling an estimated $32.3M and leaving 903,805 shares worth $56.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1309.

JP Morgan Chase first reported a position in CYTK in Q3 2013 and has held it in 38 quarters since. The position peaked at $89.8M in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

JP Morgan Chase held 903,805 shares of Cytokinetics worth $56.9M as of Q1 2026.
JP Morgan Chase sold 508,992 Cytokinetics shares in Q1 2026, an estimated $32.3M.
Cytokinetics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1309 holding.
JP Morgan Chase first reported a position in Cytokinetics in Q3 2013 and has held it in 38 quarters since.
JP Morgan Chase's Cytokinetics position peaked at $89.8M in Q4 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.